Loading...

Brilliant Violet 510™ anti-human CD8a Antibody

Pricing & Availability
Clone
RPA-T8 (See other available formats)
Regulatory Status
RUO
Workshop
IV T171
Other Names
T8, Leu2
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
RPA-T8_BV510_CD8_Antibody_FC_082512
Human peripheral blood lymphocytes were stained with CD3 FITC and CD8 (clone RPA-T8) Brilliant Violet 510™.
  • RPA-T8_BV510_CD8_Antibody_FC_082512
    Human peripheral blood lymphocytes were stained with CD3 FITC and CD8 (clone RPA-T8) Brilliant Violet 510™.
Compare all formats See Brilliant Violet 510™ spectral data
Cat # Size Price Save
301047 25 tests ¥38,720
301048 100 tests ¥67,640
Description

CD8a is a 32-34 kD type I glycoprotein. It forms a homodimer (CD8a/a) or heterodimer (CD8a/b) with CD8b. CD8, also known as T8 and Leu2, is a member of the immunoglobulin superfamily found on the majority of thymocytes, a subset of peripheral blood T cells, and NK cells (which express almost exclusively CD8a homodimers). CD8 acts as a co-receptor with MHC class I-restricted T cell receptors in antigen recognition and T cell activation, and has been shown to play a role in thymic differentiation. Two domains in CD8a are important for function: the extracellular IgSF domain binds the α3 domain of MHC class I and the cytoplasmic CXCP motif binds the tyrosine kinase p56 Lck.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Human, Cynomolgus, Rhesus
Reported Reactivity
Chimpanzee, Baboon, Pigtailed Macaque, Sooty Mangabey
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 510™ under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Brilliant Violet 510™ excites at 405 nm and emits at 510 nm. The bandpass filter 510/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 510™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

The RPA-T8 antibody does not block the binding of HIT8a antibody to CD8a. Additional reported applications of this antibody (for the relevant formats) include: immunohistochemical staining of paraformaldehyde-fixed frozen sections3 and costimulation of T cell responses4. This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The Ultra-LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 301073 & 301074).

Application References

(PubMed link indicates BioLegend citation)
  1. Knapp W, et al. Eds. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  2. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  3. Mack CL, et al. 2004. Pediatr. Res. 56:79. (IHC)
  4. Magidovich E, et al. 2007. P. Natl. Acad. Sci. USA 104:13022.
  5. Thakarl D, et al. 2008.J. immunol. 180:7431. PubMed
  6. Kmieciak M, et al. 2009. J. Transl. Med. 7:89. (FC) PubMed
  7. Thakral D, et al. 2008. J. Immunol. 180:7431. (FC) PubMed
  8. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  9. Rout N, et al. 2010. PLoS One 5:e9787. (FC)
  10. Stoeckius M, et al. 2017. Nat. Methods. 14:865. (PG)
Product Citations
  1. Ellis GI, et al. 2022. Cell Rep Med. 3:100614. PubMed
  2. Sudmeier LJ, et al. 2022. Cell Rep Med. 3:100620. PubMed
  3. Koutsakos M, et al. 2022. Immunity. 55:1316. PubMed
  4. Lima NS, et al. 2022. Nat Commun. 13:7733. PubMed
  5. Keeton R 2023. Cell Reports Medicine. 4(1):100898. PubMed
  6. Du Bruyn E, et al. 2023. Nat Commun. 14:188. PubMed
  7. Zhang B, et al. 2023. Signal Transduct Target Ther. 8:28. PubMed
  8. Rosain J, et al. 2023. Cell. 186:621. PubMed
  9. Wheatley A, et al. 2016. Sci Rep. 6: 26478. PubMed
  10. Townsley SM, et al. 2021. Cell Host Microbe. 29(4):564-578.e9. PubMed
  11. Iwahori K, et al. 2019. Sci Rep. 2.205555556. PubMed
  12. Liisborg C, et al. 2022. Acta Ophthalmol. :3. PubMed
  13. Pinto C, et al. 2023. iScience. 26:106381. PubMed
  14. Saotome K, et al. 2023. Nat Commun. 14:2401. PubMed
  15. Nakano M, et al. 2021. Front Immunol. 12:713225. PubMed
  16. Eslamizar L, et al. 2021. NPJ Vaccines. 6:15. PubMed
  17. Beraud C, et al. 2018. Virol J. 15:35. PubMed
  18. Ma KY, et al. 2021. Nat Immunol. 22:1590. PubMed
  19. Mukhamedova M, et al. 2021. Immunity. 54(4):769-780.e6. PubMed
  20. Cho JW, et al. 2021. Nat Commun. 12:6068. PubMed
  21. Sutton HJ, et al. 2021. Cell Reports. 34(6):108684. PubMed
  22. Haruna M, et al. 2020. Biol Pharm Bull. 43:399. PubMed
  23. Juno JA, et al. 2020. Nat Med. 26:1428. PubMed
  24. Liisborg C, et al. 2022. PLoS One. 17:e0269960. PubMed
  25. Wheatley AK, et al. 2021. Cell Rep. 37:109822. PubMed
  26. Tan J, et al. 2021. Sci Transl Med. 13: . PubMed
  27. Nguyen THO, et al. 2021. Immunity. 54:1066. PubMed
  28. Chandele A, et al. 2016. J Virol. 90(24):11259-11278. PubMed
  29. Aliu B, et al. 2020. Journal of Neurochemistry. 154(5):486-501. PubMed
  30. Lu Y, et al. 2021. Gastroenterology. 161:575. PubMed
  31. Keeton R, et al. 2021. Cell Host Microbe. 29:1611. PubMed
  32. Yang R, et al. 2020. Cell. 183(7):1826-1847.e31. PubMed
  33. Punik J, et al. 2021. Cell Reports. 35(13):109320. PubMed
  34. Telford W, et al. 2017. Cytometry A. 91:314. PubMed
  35. Silver J, et al. 2020. Methods Mol Biol. 2121:115. PubMed
  36. Rajamanickam V, et al. 2021. Cancer Immunol Res. 9:602. PubMed
  37. Hammitzsch A, et al. 2015. Proc Natl Acad Sci U S A. 112: 10768-10773. PubMed
  38. Severson J, et al. 2015. Cancer Immunol Res. 3:620. PubMed
  39. Yang L, et al. 2020. Genes Dis. 7:128. PubMed
  40. Ellis GI, et al. 2022. STAR Protoc. 3:101784. PubMed
  41. Port JR, et al. 2020. J Virol. 94:. PubMed
  42. Litchfield K, et al. 2021. Cell. 184(3):596-614.e14. PubMed
  43. Kariminia A, et al. 2016. Blood. 127: 3082 - 3091. PubMed
  44. Moguche AO et al. 2017. Cell host & microbe. 21(6):695-706 . PubMed
  45. Townsley SM, et al. 2021. STAR Protocols. 2(3):100771. PubMed
  46. Wang L, et al. 2021. Science. 373:. PubMed
  47. Moreno-Fernandez ME, et al. 2021. STAR Protoc. 2:100937. PubMed
  48. Fong L, et al. 2019. Cancer Discov. 10:40. PubMed
  49. Duhen R, et al. 2021. Nat Commun. 12:1047. PubMed
  50. Carnevale G,et al. 2017. Sci Rep.. 10.1038/s41598-017-14838-3. PubMed
  51. Collinson–Pautz MR, et al. 2019. Leukemia. 33:2195. PubMed
  52. Bruno L, et al. 2016. Immunol Cell Biol. 10.1038/icb.2016.49. PubMed
  53. Mothe B, et al. 2020. Front Immunol. 1.029861111. PubMed
  54. Bennstein SB, et al. 2020. eLife. 9:e55232.. PubMed
RRID
AB_2561942 (BioLegend Cat. No. 301047)
AB_2561942 (BioLegend Cat. No. 301048)

Antigen Details

Structure
Ig superfamily, homodimer or heterodimer with CD8β, 32-34 kD
Distribution

Majority of thymocytes, T cell subset, NK cells

Function
MHC class I co-receptor, thymic differentiation, T cell activation
Ligand/Receptor
MHC Class I molecules
Cell Type
Dendritic cells, NK cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay N, et al. 1993. The Leucocyte Antigen FactsBook. Academic Press Inc. San Diego.

Gene ID
925 View all products for this Gene ID
UniProt
View information about CD8alpha on UniProt.org

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-human CD8a RPA-T8 FC
APC/Cyanine7 anti-human CD8a RPA-T8 FC
Biotin anti-human CD8a RPA-T8 FC
FITC anti-human CD8a RPA-T8 FC
PE anti-human CD8a RPA-T8 FC
PE/Cyanine5 anti-human CD8a RPA-T8 FC
PE/Cyanine7 anti-human CD8a RPA-T8 FC
Purified anti-human CD8a RPA-T8 FC,CyTOF®,Costim,IHC
Alexa Fluor® 488 anti-human CD8a RPA-T8 FC
Alexa Fluor® 647 anti-human CD8a RPA-T8 FC
Pacific Blue™ anti-human CD8a RPA-T8 FC
Alexa Fluor® 700 anti-human CD8a RPA-T8 FC
PerCP anti-human CD8a RPA-T8 FC
PerCP/Cyanine5.5 anti-human CD8a RPA-T8 FC
Brilliant Violet 421™ anti-human CD8a RPA-T8 FC,ICC
Brilliant Violet 570™ anti-human CD8a RPA-T8 FC
Brilliant Violet 605™ anti-human CD8a RPA-T8 FC
Brilliant Violet 650™ anti-human CD8a RPA-T8 FC
Brilliant Violet 711™ anti-human CD8a RPA-T8 FC
Brilliant Violet 785™ anti-human CD8a RPA-T8 FC
Brilliant Violet 510™ anti-human CD8a RPA-T8 FC
Purified anti-human CD8a (Maxpar® Ready) RPA-T8 FC,CyTOF®
Alexa Fluor® 594 anti-human CD8a RPA-T8 ICC,FC
PE/Dazzle™ 594 anti-human CD8a RPA-T8 FC
APC/Fire™ 750 anti-human CD8a RPA-T8 FC
TotalSeq™-A0080 anti-human CD8a RPA-T8 PG
TotalSeq™-B0080 anti-human CD8a RPA-T8 PG
TotalSeq™-C0080 anti-human CD8a RPA-T8 PG
Ultra-LEAF™ Purified anti-human CD8a RPA-T8 FC,CyTOF®,Costim,IHC
Spark Violet™ 423 anti-human CD8a Antibody RPA-T8 FC
Spark Red™ 718 anti-human CD8a RPA-T8 FC
Spark PLUS UV395™ anti-human CD8a RPA-T8 FC
Go To Top Version: 3    Revision Date: 07/13/2015

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account